Document is current

Any future updates will be listed below

Phase II study of fixed dose-rate gemcitabine plus S-1 as a second-line treatment for advanced biliary tract cancer

Crossref DOI link: https://doi.org/10.1007/s00280-017-3461-z

Published Online: 2017-10-25

Published Print: 2017-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark